Type 1 Diabetes Clinical Trial
— Hypo-Heart-1Official title:
Hypoglycaemia and Cardiac Arrhythmias in Type 1 Diabetes
Verified date | January 2022 |
Source | Steno Diabetes Center Copenhagen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The investigators hypothesise that patients with type 1 diabetes have clinically relevant, but often unrecognised, episodes of arrhythmias linked to episodes of hypoglycaemia and/or clinically significant fluctuations in plasma glucose.
Status | Completed |
Enrollment | 30 |
Est. completion date | December 20, 2021 |
Est. primary completion date | December 20, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Informed and written consent - Type 1 diabetes diagnosed according to the criteria of the World Health Organization (WHO) - Age 18-80 years - Fulfilling at least one of the below criteria*: 1. Recurrent hypoglycaemia (defined as >1 episode/week with a plasma glucose measurement =3.9 mmol/l within the last 4 weeks) 2. An episode of severe hypoglycaemia within the last year (according to the ADA definition, an event requiring assistance of another person to actively administer carbohydrates and/or glucagon, or take other corrective actions) 3. Hypoglycaemic symptom unawareness (history of impaired autonomic response during hypoglycaemia) (*The aim is that all patients will fulfil criteria a or b. If the targeted sample size cannot be recruited, patients fulfilling criteria c will be included) - Insulin treatment - One or more clinical relevant complications to diabetes defined as**: 1. Nephropathy (creatinine >130 µmol/l and/or microalbuminuria) 2. Macrovascular disease defined as coronary disease (stable angina pectoris. previous unstable angina pectoris or myocardial infarction), cerebrovascular disease (previous stroke or transitional cerebral ischaemia), and peripheral vascular disease (previous intermittent claudication or prior acute ischemia) 3. Peripheral neuropathy with vibration perception threshold of >25 volt determined by biothesiometry 4. Moderate to severe retinopathy - Well-functioning ILR during run-in period (acceptable readings judged by an arrhythmologist) - Participation in the extended study (**The aim is that all patients will fulfil criteria a or b. If the targeted sample size cannot be recruited, patients fulfilling criteria c or d will be included) Exclusion Criteria: - Arrhythmia diagnosed prior to the screening visit - ICD or pacemaker at the time of inclusion - Severe heart failure (left ventricular ejection fraction <25%) - Structural heart disease (Wolf-Parkinson-White syndrome, congenital heart disease, severe valve disease) - Thyroid dysfunction (except for well-regulated eltroxine substituted myxoedema) |
Country | Name | City | State |
---|---|---|---|
Denmark | Clinical Metabolic Physiology, SDCC | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Steno Diabetes Center Copenhagen | Hillerod Hospital, Denmark, University Hospital, Gentofte, Copenhagen, University of Copenhagen |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of cardiac arrhythmias during hypoglycaemia, euglycaemia, hyperglycaemia. | Incidence of clinically relevant arrhythmias during hypoglycaemia (plasma glucose =3.9 mmol/l) compared to euglycaemia and hyperglycaemia. | Within 12 months | |
Secondary | Prevalence of cardiac arrhythmias | Prevalence of clinically relevant arrhythmias | Within 12 months | |
Secondary | Cardiac arrhythmias during LGV, HGV. | Clinical relevant arrhythmias during low glucose variability (LGV), defined as variations in plasma glucose below or equal to 5 mmol/l within two hours preceding an arrhythmic event, compared to high glucose variability (HGV), defined as variations in plasma glucose above 5 mmol/l within two hours preceding an arrhythmic event. | Within 12 months | |
Secondary | The relationship between cardiovascular disease at baseline and clinically relevant arrhythmias in relation to hypoglycaemia and HGV | The relationship between cardiovascular disease (heart failure and ischaemic heart disease) at baseline and clinically relevant arrhythmias in relation to hypoglycaemia and HGV | Within 12 months | |
Secondary | The relationship between pharmacological treatment at baseline and clinically relevant arrhythmias in relation to hypoglycaemia and HGV | The relationship between pharmacological treatment at baseline and clinically relevant arrhythmias in relation to hypoglycaemia and HGV | Within 12 months | |
Secondary | The relationship between diabetes complication status at baseline and clinically relevant arrhythmias in relation to hypoglycaemia and HGV | The relationship between diabetes complication status (neuropathy, nephropathy, retinopathy) at baseline and clinically relevant arrhythmias in relation to hypoglycaemia and HGV | Within 12 months | |
Secondary | Hypoglycaemia and cardiac arrhythmia | The correlation between prevalence and total duration of hypoglycaemia and risk of clinically relevant arrhythmias | Within 12 months | |
Secondary | Plasma glucose variation and cardiac arrhythmias | The correlation between plasma glucose variation (variation in plasma glucose (? mmol/l) within two hours of the event) and risk of clinically relevant arrhythmias | Within 12 months | |
Secondary | CV, SD, ADRR, LBGI, HBGI, CONGA-1 and cardiac arrhythmias | The correlation between measures of glycaemic variability (coefficient of variation (CV), standard deviation (SD), average daily risk range (ADRR), low blood glucose index (LBGI), high blood glucose index (HBGI) and continuous overlapping net glycaemic action (CONGA-1)) and risk of clinically relevant arrhythmias | Within 12 months | |
Secondary | Mean amplitude of glycaemic excursions (MAGE) and cardiac arrhythmia. | Difference in mean amplitude of glycaemic excursions (MAGE) two hours preceding an arrhythmic event versus MAGE during non-event | Within 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|
||
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A |